share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1:證券上市註冊聲明
美股SEC公告 ·  2024/11/23 05:41

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
Cardio Diagnostics Holdings, Inc. 於2022年10月通過合併成立,專門從事人工智能驅動的心血管疾病DNA生物標誌物測試。儘管有Epi+Gen CHD™ 和PrecisionCHD™ 等創新產品,但該公司報告稱,2023年收入微乎其微,淨虧損840萬美元。截至2024年9月30日,它持有300萬美元的現金。該公司根據CDIO在納斯達克交易,但收到了不遵守1美元最低出價的通知。領導層包括首席執行官 Meeshanthini Dogan 和首席財務官 Elisa Luqman。Cardio Diagnostics通過各種方式籌集了資金,包括2023年3月的500萬美元可轉換債券和2024年2月的100萬美元私募債券。主要風險涉及有限的運營歷史和對額外資本的需求。該公司專注於通過遠程醫療和醫療保健提供商將其測試商業化。
Cardio Diagnostics Holdings, Inc. 於2022年10月通過合併成立,專門從事人工智能驅動的心血管疾病DNA生物標誌物測試。儘管有Epi+Gen CHD™ 和PrecisionCHD™ 等創新產品,但該公司報告稱,2023年收入微乎其微,淨虧損840萬美元。截至2024年9月30日,它持有300萬美元的現金。該公司根據CDIO在納斯達克交易,但收到了不遵守1美元最低出價的通知。領導層包括首席執行官 Meeshanthini Dogan 和首席財務官 Elisa Luqman。Cardio Diagnostics通過各種方式籌集了資金,包括2023年3月的500萬美元可轉換債券和2024年2月的100萬美元私募債券。主要風險涉及有限的運營歷史和對額外資本的需求。該公司專注於通過遠程醫療和醫療保健提供商將其測試商業化。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息